Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Dec 28, 2021

Cantargia announces publication of two scientific articles on nadunolimab

Dec 13, 2021

(R) Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model

Dec 1, 2021

(R) Cantargia reports opposition against recently granted European patent

Nov 11, 2021

(R) Cantargia publishes interim report for third quarter 2021

Nov 8, 2021

(R) Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10

Nov 8, 2021

Invitation to presentation of Cantargia’s report for the third quarter of 2021 on November 11 at 3.00 p.m. CET

Oct 29, 2021

(R) Nomination Committee appointed ahead of 2022 Annual General Meeting

Oct 22, 2021

(R) Cantargia reports treatment of first patient in CESTAFOUR clinical trial

Oct 14, 2021

(R) Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer

Sep 30, 2021

(R) Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye